Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03440567
Title Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

diffuse large B-cell lymphoma

mantle cell lymphoma

Therapies

Avelumab + Carboplatin + Etoposide + Ifosfamide + Rituximab + Utomilumab

Avelumab + Ibrutinib + Rituximab + Utomilumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.